Creo Medical Regulatory News (CREO)

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Creo and Khalifa University establish a Strategic Research Collaboration to capitalise on Creo's Intellectual Property (IP) estate alongside Khalifa University's research expertise

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, and internationally highly-ranked Khalifa University of Science and Technology in Abu Dhabi, have established a strategic collaboration to explore innovative commercial opportunities, with an initial focus on healthcare challenges relevant to the population in the United Arab Emirates (UAE), and the wider Middle East and North Africa region using the resources and expertise available at Khalifa University in Abu Dhabi to capitalise on Creo's Intellectual Property (IP) estate.

Having recently performed first procedures in the UAE, Creo will also leverage the collaboration to support its regional distributors and core clinical operations, including the development of clinical research with key customers in Abu Dhabi and the wider region.

This collaboration is aligned with Khalifa University's strategic objective to enhance enterprise targeted research with highly innovative partners. Khalifa University's deep tech initiative encompasses research partnerships but also investments in start-ups, incubation services, a science and technology park, an endowment fund, and a continuing education programme. This collaboration is also in line with the UAE Government's policy and helps further Khalifa University's ambition to become one of the world's premier research institutions.

Craig Gulliford, Chief Executive Officer of Creo Medical, said: "Creo has broad and deep IP that underpins its Kamaptive Electrosurgical Advanced Energy and Non-Thermal Plasma Sterilisation technology used in current products as well as offering significant potential for future products and treatments. As part of our strategy, we are driven to exploit our IP either directly or in partnership with third-parties, as shown by our Robotic Assisted Surgery collaborations. Khalifa University is a research-intensive organisation with a similar drive to develop and commercially exploit leading technologies, at scale and on a global basis. The combination of Creo's people, technology and IP with Khalifa University's teams, technologies, facilities and resources represents a great opportunity for both organisations to advance and commercialise incremental technology and products and enhance research profiles internationally."

Professor Sir John O'Reilly, President, Khalifa University, said: "We are delighted to enter into this strategic collaboration with Creo that marks a significant milestone in our ongoing efforts to advance medical science, technology and innovation, seeing it taken through to commercialisation and application to the benefit of patients. Such a collaboration between an internationally highly-ranked university and Creo, a leader in medical device technology, bears testament to our shared commitment to obtaining healthcare solutions relevant to UAE and globally. By combining Creo's groundbreaking intellectual property and Khalifa University's extensive research capabilities and resources, we are poised to explore new opportunities and develop impactful solutions to healthcare challenges."

Enquiries:

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

About Khalifa University of Science and Technology

Khalifa University of Science and Technology, the UAE's top-ranked research-intensive institution, focuses on developing world leaders and critical thinkers in science, engineering and medicine. The world-class university endeavors to be a catalyst to the growth of Abu Dhabi and the UAE's rapidly developing knowledge economy, as an education destination of choice and a global leader among widely acknowledged international universities.

For more information, please visit: http://www.ku.ac.ae/